What the evidence says
Brello Health positions itself as a budget-forward telehealth pathway to GLP‑1 therapy, emphasizing simple pricing and a highly guided digital intake. The storefront centers on two products—compounded semaglutide and tirzepatide—sold as three‑month plans with the monthly equivalent displayed prominently. We validated that each plan clearly lists what’s included (provider-led review, supplies, and shipping), and that the offer is framed as a subscription with renewal language that matters to budgeting. The standout operational detail is the renewal cadence: despite “every 3 months” marketing, billing recurs every 10 weeks, which can catch patients off guard if they don’t read past the price card.
Our testing of the user experience shows a predictable four‑step flow: select a plan, complete a health questionnaire, undergo provider review, then receive shipment if approved. Shipping language is unusually explicit: standard prep is 5–7 business days plus ~2‑day transit, with a live banner that updates when volume spikes (recently 11–15 business days). That transparency is helpful, though it also signals variability—patients needing rapid initiation may be disappointed during surges. We also confirmed the “full refund if not approved” statement and observed a help‑center article aligning with the refund policy’s same‑day rule and service fee.
Clinically, Brello’s model connects patients to independent providers who determine eligibility and titration; Brello itself is non‑clinical. Medication is dispensed by partner pharmacies identified in the legal documents, and the site repeatedly discloses that compounded medications are not FDA‑approved and are intended when an FDA‑approved option isn’t suitable. This level of disclosure is above average in the category and sets expectations appropriately around compounding. We also noted prescription-policy language that limits certain drugs (e.g., no DEA‑controlled substances) and affirms the patient’s right to choose pharmacy, a good signal for continuity of care.
Pricing is Brello’s calling card. We verified semaglutide at a headline $399 and tirzepatide at $499 under three‑month plans, with marketing that translates to “$133 per month” and “$166 per month,” respectively. Importantly, the auto‑renew is every 10 weeks, not a full quarter—this affects annualized cost and inventory planning. The fine print around money is strict: only same‑day cancellations after a telehealth visit qualify for a refund, minus a $50 service fee; no refunds once medication is dispensed. Arbitration in Harris County, Texas, and “risk of loss” passing at carrier handoff round out key policy implications for consumers.
Bottom line: Brello delivers on clear pricing, candid compounding disclosures, and a predictable digital intake, but demands careful reading of renewal and refund terms. We recommend it for cost‑conscious, self‑managing adults comfortable with injections and asynchronous support who can plan around variable fulfillment timelines. Those who prefer brand‑name pens, generous return windows, or white‑glove support may be better served elsewhere. As with any compounded therapy, we advise confirming the dispensing pharmacy’s licensure and discussing medical necessity with the prescribing clinician before proceeding.
- Transparent flat‑rate plan pricing with monthly equivalents.
- Auto‑renew cadence is every 10 weeks, not a full quarter.
- Strict refund rules: same‑day cancellation only; $50 fee.
- Clear compounding disclosures; non‑HIPAA‑covered entity; arbitration in Harris County, TX.
